CCA
RCUS icon

Catalyst Capital Advisors’s Arcus Biosciences RCUS Stock Holding History

Catalyst Capital Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-247
Closed -$4K – 549
2018
Q1 		$4K Buy
+247
New +$4.11K ﹤0.01% 429

Other funds holding RCUS

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Catalyst Capital Advisors's RCUS Position: Q2 2018 in Review

Catalyst Capital Advisors sold out of Arcus Biosciences (RCUS) in Q2 2018, closing a stake of 247 shares — an estimated $4K sold.

Catalyst Capital Advisors first reported a position in RCUS in Q1 2018 and held it in 1 quarter. The position peaked at $4K in Q1 2018. 64 funds tracked by Wall St. Rank hold RCUS as of Q2 2018.

  • Catalyst Capital Advisors reported no remaining Arcus Biosciences position as of Q2 2018 after selling out during the quarter.
  • Catalyst Capital Advisors sold 247 Arcus Biosciences shares in Q2 2018, an estimated $4K.
  • Catalyst Capital Advisors first reported a position in Arcus Biosciences in Q1 2018 and held it in 1 quarter.
  • Catalyst Capital Advisors's Arcus Biosciences position peaked at $4K in Q1 2018.
  • 64 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2018.

Based on Catalyst Capital Advisors's 13F filing for Q2 2018, filed 7 Aug 2018.